Anterior gradient-2 (AGR2) expression was examined in a series of prostate cell lines and in an archival set of prostate tissues. The relative levels of AGR2 expression in the malignant cell lines PC-3 and PC-3M were, respectively, 5.370.1 and 3.870.2 times that detected in the benign cell line PNT-2. Immunohistochemical staining in 106 cases showed that amongst seven normal cases, one (14.3%) was unstained, five (71.4%) stained weakly positive and one (14.3%) stained moderately positive. Amongst 34 benign prostate hyperplastic (BPH) cases, 12 (35.3%) were unstained, 18 (52.9%) stained weakly positive and four (11.8%) stained moderately positive. Amongst 65 carcinomas, three (4.6%) were unstained, 14 (21.5%) stained weakly positive, 19 (29.2%) stained moderately positive and 29 (44.9%) stained strongly positive. AGR2 expression in carcinomas was significantly higher than that in BPH (v 2 -test, Po0.001). Kaplan-Meier survival analysis showed that increased AGR2 expression was significantly (log rank test, P ¼ 0.007) associated with reduced patient-survival time. Increased joint Gleason score (GS) was significantly (log rank test, P ¼ 0.001) associated with poor patient survival. However, neither prostate specific antigen (PSA) level, nor androgen receptor (AR) index, was significantly associated with patient-survival time. Increased AGR2 expression was significantly correlated with high GS (two-sided Fisher's exact test, Po0.001) and PSA levels (Mann-Whitney U-test, P ¼ 0.047), but not significantly related to the level of AR (Mann-Whitney U-test, P ¼ 0.286). These results suggest that increased AGR2 expression is a valuable prognostic factor to predict the clinical outcome of the prostate cancer patients.
Prostate cancer is the most common male cancer and a significant health problem in industrialized countries. [1] [2] [3] It was estimated that 232 090 men had been diagnosed with prostate cancer and 30 350 died from the disease in the year 2005. 4 During the past several years, great effort has been made to find out those genes promoting or suppressing malignant progression of prostate cancer cells 3, 5 and many new genes involved in carcinogenesis and metastasis have been identified. 6, 7 In contrast to rapid development in identification of new oncogenes and tumour suppressor genes, progress in searching for new prognostic and diagnostic markers from cancerrelated genes has been relatively slow. In view of the controversies existing in the accuracy and reliability of currently used biomarkers, such as prostate specific antigen (PSA), 8 it is of great importance for prostate cancer treatment and management to identify and characterize new molecular markers for prediction of the patient outcomes.
Androgen-inducible gene anterior gradient-2 (AGR2), also known as HAG-2 9 and Gob-4, 10 is the human orthologue of the secreted Xenopus laevis AGR protein (XAG-2) which has been known to play a patterning role in frog embryos.
11 AGR2 was originally cloned as a gene that was differentially expressed between estrogen receptor (ER)-positive carcinoma cell lines MCF-7 and ER-negative benign breast cell lines MDA-MB-231 9 and Hama 123. 12 AGR2 is expressed at a higher level in the human breast cancer cell line MCF-7 than in the benign cell line Hama 123. Previous investigation suggested that expression of AGR2 was significantly associated with poor outcome in patients with ER-positive breast cancer. 13 In comparison to research in breast cancer, the role of AGR2 in prostate cancer was not very clear. AGR2 was highly induced by androgen in an androgen receptor (AR)-dependent manner and the expression of AGR2 was markedly increased at both mRNA and protein levels in prostate cancer cells compared with their benign counterparts, 14 indicating that AGR2 expression might be involved in the malignant progression of prostate cancer.
In this study, we aimed to find out whether AGR2 can be used as a prognostic marker for prostate cancer diagnosis. The expression status of AGR2 in different prostate cell lines and in an archival set of 106 prostate tissues has been examined. The relationship between increased expression of AGR2 and the time of patient survival has been carefully assessed, and the expression of AGR2 has also been correlated with Gleason score (GS) of the carcinomas, levels of PSA and AR.
Materials and methods

Cell lines and culture conditions
Five human prostate cell lines were used in this work: the benign prostate epithelial cell line PNT-2, 15,16 the weakly malignant cell lines LNCaP, 17 highly malignant cell lines Du-145, 18 PC-3 and PC-3M. 19 The cells were cultured as monolayers in RPMI 1640 (Invitrogen, Paisley, UK) supplemented with 10% (v/v) FCS (Biosera, East Sussex, UK), penicillin (100 units/ml), streptomycin (100 mg/ml) (Invitrogen), hydrocortisone (50 ng/ml) and testosterone (50 ng/ml) (Sigma, Grillingham, UK).
Detection of AGR2 protein in cell lines
AGR2 protein expressed in various cell lines was detected by western blot, using an ECL light-emitting non-radioactive kit (Amersham Bioscience, Bucks, UK) as described previously. 20 Proteins were extracted from different cell lines and equal amounts of each sample (20 mg) were quantified with a Coomassie Protein Assay Reagent kit (Biorad, Hemel, Hempstead, UK). Samples containing equal amounts of total protein were subjected to SDS-PAGE in 12% (w/v) polyacrylamide gels together with molecular weight markers. Recombinant AGR2 protein flanked with a histidine tag containing a protease factor X cleavage site was produced in Escherichia coli, purified as described previously 12 and loaded on the left side of the gel to act as a size control. The separated proteins were transferred onto a nitrocellulose membrane (Hybond, Amersham Biosciences) at 100 V for 2 h at 41C. The membrane was first incubated with preblocking reagents (ProtoBlock, National Diagnostics, Atlanta, USA) for 1 h at room temperature and then incubated with affinity-purified, in-house rabbit polyclonal anti-human AGR2 antibody 12 with 1/500 dilution overnight at 41C. The membrane was then incubated with polyclonal swine anti-rabbit immunoglobulins/ HRP (DAKO, CAMBS, UK) with 1/1000 dilution for 1 h at room temperature and bound antibodies were revealed by chemiluminescene (ECL, Amersham BioTech) and recorded on Kodak XAR-5 film. The bands were then scanned using Alpha-Imager 2000 software (Alpha Innotech, Cannock, UK) and the intensity of band was obtained by measuring peak area. The relative levels of AGR2 expression in different cell lines were obtained by comparing the intensity of bands. The level of AGR2 expressed in benign cell line PNT2 was set at 1. To standardize the quantitative measurements, the blot was incubated with specific anti-human actin monoclonal antibody (Sigma) and possible loading errors were corrected by relating the images to the b-actin bands. Results were expressed as the mean (7s.d.) of four separate measurements.
Human prostate tissues
The human prostatic tissues were an archival set with up-to-date records held within the surgical pathology archive in the Molecular Pathology Laboratory. Tissues were taken from 65 prostate adenocarcinoma patients with a mean age of 73 years and from 34 benign prostate hyperplastic (BPH) patients with a mean age of 67.5 years through Trans-urethral Resection of Prostate in the Royal Liverpool University Hospital during the 5-year period of 1995-2000. The seven normal prostate tissues were taken from road traffic accident victims (mean age 48 years) who did not have a history of any prostatic diseases. Our study was performed in accordance with the Medical Research Council guidelines and was approved by Liverpool Local Science Ethics Committee (project reference number: Ke: 02/19). Four-micrometer sections of formalin-fixed and paraffin-embedded tissues were cut and processed, as described previously. 21, 22 Tissue sections were examined independently by two qualified observers which were blinded to the clinical data and classified as normal, BPH and carcinomas. Carcinomas were further classified according to their GS. 23 PSA level at the initial diagnosis was obtained through telepath system and classified into two groups of low (o4-10 ng/ml) and high (410 ng/ml). 24 Detection of protein expression in prostate tissues AGR2 expression in human prostate tissues was detected by immunohistochemical staining. The procedures for tissue staining were similar to those described previously. 6, 22 After dewaxing in xylene and rehydration in graded ethanol, sections were immersed in methanol containing 3% (v/v) hydrogen peroxide for 12 min to block endogenous proxidase, followed by rinsing in running tap water and immersing in distilled water. Antigen retrieval was then achieved with pressurecooker pretreatment for 3 min. Sections were incubated within house (12) affinity-purified AGR2 antibody with a 1/500 dilution for 1 h. Bound antibodies were detected with 100 ml of reagents from Envision System Horseradish Peroxidase kit (Dakocytomation, Ely, UK) for 30 min and the reaction was visualized with DAB (3-3 0 -diaminobenzidine) for 10 min. Afterward, sections were briefly counterstained with hematoxylin and mounted with dibutyl phthalate xylene (DPX). To test its specificity, the antibody was incubated with 10 mg/ml of recombinant human AGR2 protein at 41C overnight and applied to sections as described above; this procedure completely blocked any immunolabelling. ARs were detected using monoclonal anti-human AR antibody (Dako) on the same set of tissues at a 1/100 dilution of the primary antibody following the pressurecooker pretreatment.
Immunoreactive scores of AGR2 were established by the method described previously 25 with some modifications. Stains were first assessed by the percentages of cells stained to obtain a percentage score (1-4) [1 (o5%), 2 (5-30%), 3 (31-70%), 4 (470%)); then by intensity of the stains to obtain an intensity score (1) (2) (3) (4) 
by multiplying the percentage score and the intensity score. The immunohistochemical stains were finally classified as negative (1), weakly positive (2-6), moderately positive (7) (8) (9) (10) (11) and strongly positive (12) (13) (14) (15) (16) . To assess the staining index of AR, each slide was scored by the intensity of staining and percentage of positive cells (labelling frequency, %). The grading scale for intensity ranged from no signal (0) to strong signal (3); grade 2 corresponded to a moderate signal seen in low-tointermediate power and grade 1 corresponded to weak signal in intermediate and high power. The labelling frequency was defined as 0 (0%), 1(1-30%), 2 (31-70%) and 3 (70-100%). AR index was obtained by multiplying the grade of intensity by the labelling frequency for each case. AR expression has been defined as low (o4) and high (X4). 26 
Statistical analysis
Statistical analyses were performed using the SPSS package, version 13.0 (SPSS Inc., Chicago, IL, USA). Association between the AGR2 expression and the nature of the prostate tissues (normal, benign and malignant) was assessed by two-sided Fisher's exact test. Correlations between AGR2 expression, PSA level, AR expression and GS in prostate carcinoma and patient-survival time were evaluated by using Kaplan-Meier plots and differences between groups of patients were assessed by the log rank test. Box plot and Mann-Whitney U-test were used to assess correlations between AGR2 and PSA level, AGR2 and AR and PSA levels and GS. P-valueso0.05 were considered statistically significant.
Results
AGR2 expression in prostate cell lines
Western blot analysis detected a single AGR2 band with a size of 20 kDa in the benign PNT-2 cell line and in highly malignant cell lines, PC-3 and PC-3M (Figure 1a) . The detailed quantitative measurements of relative AGR2 levels expressed in different cell lines are shown in Figure 1b . When the level of AGR2 expressed in the PNT2 cells was set at 1, the relative levels of AGR2 in the malignant cell lines PC3 and PC3M were 5.2970.14 and 3.8170.23 (mean7s.d.), respectively. No AGR2 protein was detected in the weakly cell lines LNCaP and highly malignant Du145.
AGR2 expression in prostate tissues
Examples of immunohistochemical stains of different prostate tissues with rabbit polyclonal anti-human AGR2 antibody were shown in Figure 2 . In normal prostate gland, AGR2 staining was localized predominantly to the cytoplasm of luminal cells of prostate glands, whereas in the prostate carcinomas, both cytoplasmic and nuclear stains were observed. When the antibody was neutralized with the recombinant AGR2 protein, the stain was completely blocked (Figures 2g and h 
AGR2 expression and patient survival
The relationship between the strength of AGR2 staining and the patient-survival time are shown in Figure 3a .
For the patients with strongly positive AGR2 stains, the median survival time was 36.3 months, which was significantly shorter than 75 months and 80 months for patients with moderately (log rank test, P ¼ 0.03) and weakly (log rank test, P ¼ 0.006) positive AGR2 stains, respectively. Overall survival time was significantly (log rank test, P ¼ 0.007) reduced with increased AGR2 stains. The difference in median survival time between moderately and weakly positive AGR2 staining groups was not significant (log rank test, P ¼ 0.25).
GS and patient survival
To assess the relationship between the GS and patient survival, 65 carcinoma cases were divided into the weakly malignant group with GS of p5, the moderately malignant group with GS of 6-7 and the highly malignant group with GS of 8-10. The median survival time of patients with weakly, moderately and highly malignant carcinomas was 80, 48 and 24 months, respectively (Figure 3b ). The reduced survival time was significantly (log rank test, P ¼ 0.002) associated with the increased degree of malignancy.
PSA and patient survival
The correlation between PSA level and patient-survival time is shown in Figure 3c . The median survival time for (e) A highly malignant carcinoma (GS 9) stained strongly positive ( Â 100). (f) Strongly positive stain was observed in a malignant carcinoma (large arrow) whereas no stain was observed in the adjacent benign areas (small arrow) within the same tissue sample ( Â 100). (g) and (h) are test stains for antibody specificity: the moderately malignant carcinoma stained strongly positive (g); but when the recombinant AGR2 protein was added to neutralize the polyclonal antibody in the immunohistochemical reaction, no stain (h) was observed on the same carcinoma sample ( Â 100).
AGR2 expression in prostate cancer Y Zhang et al patients with low (o4 ng/ml) and borderline (4-10 ng/ ml) PSA level was 60.9 months compared with 48.3 months in patients with high (410 ng/ml) PSA levels. Although survival time has been reduced in patients with high PSA level, the association of the patient PSA level with the length of the survival time was not significant (log rank test, P ¼ 0.108).
AR and patient survival
The correlations between AR and survival are shown in Figure 3d . The median survival time for patients with low (index o4) and high (index X4) AR levels was 60.6 
Correlation of AGR2 expression with GS
Amongst 15 GSp5 carcinomas, 13 (86.6%) stained weakly positive and two (13.3%) stained moderately positive. Amongst 26 GS 6-7 carcinomas, two (7.7%) were unstained, 15 (57.6%) stained moderately positive and nine (34.6%) stained strongly positive. Amongst 24 GS 8-10 carcinomas, one (4.1%) was unstained, one (4.1%) stained weakly positive, two (8.3%) stained moderately positive and 20 (83.3%) stained strongly positive ( Table 1 ). The strengthened AGR2 staining was significantly (two-sided Fisher's exact test, Po0.001) associated with the increased GS of the carcinomas.
AGR2 expression and PSA level
The correlation between levels of PSA and AGR2 expression is shown in Figure 4a . For patients with weak, moderate and strong AGR2 stains, the median PSA level was 6.85, 6.20 and 10.3 ng/ml, respectively. Box plot analysis showed that the level of PSA in the patients with strong AGR2 staining was significantly higher than that of patients with moderate (Mann-Whitney U-test, P ¼ 0.015) and weak (Mann-Whitney U-test, P ¼ 0.007) staining. However, the difference in patient PSA levels between moderate and weak AGR2 stained groups was not significant (Mann-Whitney U-test, P ¼ 0.095).
AGR2 expression and AR index
The correlation of AR index with AGR2 expression was shown in Figure 4b . For patients with weak AGR2 stains, the median AR index was 1. For patients with moderate and strong AGR2 stains, the median AR indexes were 4. Box plot analysis showed that the difference in patient AR indexes either between strong and moderate AGR2-stained groups (Mann-Whitney U-test, P ¼ 0.600), or between strong and weakly stained groups (MannWhitney U-test, P ¼ 0.286), was not significant.
PSA and GS
The correlation of PSA levels and GS was shown in Figure 4c . For patients with GS p5, GS 6-7 and GS 8-10 carcinomas, the median PSA levels were 6.2, 7.05 and 27.40 ng/ml, respectively. Box plot analysis showed that the PSA level was significantly higher in patients with GS 8-10 carcinomas than those with GS p5 (MannWhitney U-test, P ¼ 0.001) and GS 6-7 carcinomas (Mann-Whitney U-test, P ¼ 0.02). However, the difference in patient PSA levels between the GS 6-7 and GS p5 carcinoma groups was not significant (MannWhitney U-test, P ¼ 0.308).
Discussion
AGR2 was originally found in human breast cancer. Using suppression-subtractive hybridization, it was found that 29 genes expressed in ER-positive breast carcinomas might contribute to its less aggressive phenotype when compared with ER-negative tumours. The ER expression in eight breast carcinoma cell lines was correlated with the expression of one of the 29 genes, DEME2. 27 After screening an ER-positive breast cancer cell cDNA library with the DEME2 probe and searching expression sequence tags (EST) database, AGR2, human homologue of the XAG-2 protein was discovered. 9 It was found that XAG-2 was a direct inducer of anterior neural fate of Xenopus ectoderm and its overexpression did not result in activation of cephalic hedgehog nor in induction of noggin expression. 11 The deduced 175-amino acid soluble AGR2 protein, which is 91 and 47% identical to mouse and frog homologues, respectively, contains a signal peptide. Northern blot analysis detected AGR2 transcripts of 0.9 kb in lung cancer cells and 1.6 kb in ERpositive breast cancer cells; whereas a weaker expression was detected in pancreas. RNA dot blot analysis detected a strong AGR2 expression in trachea, lung, stomach, colon, prostate and small intestine. 9 By immunohistochemistry and real-time quantitative PCR analyses, it was found that AGR2 mRNA and protein exhibited similar increase in breast cancer tissues and expression of AGR2 was correlated with expression of ER. 28 In a recent study, it was found that there was a significantly progressive reduction in patient-survival time with increasing AGR2 staining solely in ER-positive cases. 13 Further analysis suggested that AGR2 was a prognostic marker in breast cancer for the subgroups of nodal negative stage I tumors. 29 Recently, preliminary investigations were performed on the possible role of AGR2 in other diseases, such as inflammatory bowel disease 30 and prostate cancer. 14, 31 Although it was reported that the overexpression of AGR2 was detected in prostate cell lines and carcinomas, its actual role in malignant progression was not clear. Its prognostic significance in patient survival has not been carefully investigated.
In this study, we first examined the AGR2 expression status in five commonly used prostate cell lines (Figure 1 ). We found that two of the four (50%) malignant cell lines expressed 3.8 to 5.3 times more AGR2 than the benign PNT-2 cells, whereas another two malignant cell lines did not express AGR2. This result showed that the elevated expression of AGR2 is associated with increased malignant characteristics in 50% of the cell lines examined, indicating that it is possible that the increased AGR2 expression plays a promoting role in the development and metastasis of prostate cancer cases. 32, 33 The immunohistochemical analyses (Table 1) showed no significant (two-sided Fisher's exact test, P ¼ 0.67) difference in AGR2 staining strength between normal and BPH cases. However, significant (two-sided Fisher's exact test, Po0.001) increase in AGR2 level was observed in carcinomas compared with normal and BPH cases. Furthermore, AGR2 staining was significantly stronger (two-sided Fisher's exact test, Po0.001) in moderately malignant tissues than that in weakly malignant tissues. Similarly, highly malignant carcinomas exhibited significantly stronger AGR2 stains than weakly (two-sided Fisher's exact test, Po0.001) and moderately (two-sided Fisher's exact test, Po0.01) malignant carcinomas. These results suggest that, increased AGR2 expression was significantly associated with increased malignant changes as reflected by the increased GS. Thus increased AGR2 expression may be an indicator for the malignant progression of prostate cancer.
The overall increment of AGR2 expression was significantly (log rank test, P ¼ 0.007) associated with the reduced time of patient survival. The survival time of the patients with strong AGR2 staining was significantly shorter than that of the patients with moderate and weak AGR2 staining (Figure 3a) . This result showed that the overall increased AGR2 expression was significantly associated with the poor prognosis in terms of patient survival. Further assessment showed that the patientsurvival time (Figure 3b ) was significantly (log rank test, P ¼ 0.002) correlated in a reciprocal manner to the degree of malignancy classified by GS. These results suggested that like GS of the carcinomas, the AGR2 staining strength was also a very useful parameter in predicting the patient outcome.
PSA is currently the most widely used marker for prostate cancer. 34, 35 In this study, although the survival time was reduced with increased PSA level (Figure 3c) , the increased PSA level was not significantly (log rank test, P ¼ 0.108) associated with the reduced patientsurvival time. Thus, in this group of patients studied, PSA level was not a reliable prognostic marker. AR was believed to play an important role in regulation of the malignant progression of prostate cancer, 26, 36 but the result (Figure 3d ) in this study showed there was no significant (log rank test, P ¼ 0.485) association between AR index and the time of patient survival.
When the correlations between AGR2 expression and PSA level (Figure 4a ) and between AGR2 and AR index ( Figure 4b) were assessed, the level of PSA in the patients with strong AGR2 staining was significantly higher than that of the patients with moderate staining (MannWhitney U-test, P ¼ 0.007) and weak staining (MannWhitney U-test, P ¼ 0.015), but the difference in patient PSA levels between moderate and weak AGR2 stains was not significant (Mann-Whitney U-test, P ¼ 0.095), suggesting that the level of AGR2 expression was partially associated with the level of PSA. In contrast, the difference in patient AR indices was neither significant between strong and moderate AGR2 stained cases (Mann-Whitney U-test, P ¼ 0.600), nor between strong and weakly stained cases (Mann-Whitney U-test, P ¼ 0.286). These results suggest that the expression of AGR2 was not related to that of AR in the cases of prostate cancer studied in this work, although AGR2 was closely related to ERs in breast cancer. 12 More study is required to find out why AGR2 acts in such a different manner in breast and prostate cancers.
The assessment (Figure 4c ) showed that PSA level was significantly higher in patients with highly malignant carcinomas than those with weakly (Mann-Whitney Utest, P ¼ 0.001) and moderately (Mann-Whitney U-test, P ¼ 0.02) malignant carcinomas, whereas the difference between the moderately and weakly malignant carcinoma cases was not significant (Mann-Whitney U-test, P ¼ 0.308). This result showed that although PSA is not suitable to be a prognostic marker, it can partially reflect the degree of malignancy of the carcinomas in these groups of patients.
In conclusion, AGR2 was expressed in higher levels in some malignant prostate cell lines and tissues compared with the normal and BPH cases. The increased AGR2 expression was significantly associated with the increased malignancy of the carcinoma and the reduced survival time of patients. Therefore, the increased AGR2 expression in prostate cancer Y Zhang et al expression of AGR2 may be a valuable prognostic marker to predict the outcome of patients with prostate cancer.
